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SUMMARY 
Stress is an important homeostatic function which may not always be entirely positive for the 
individual. It has been found that stress both has the ability to amplify and reduce pain. Also, 
pain may induce stress and fear. An important element of pain assessment in horses is the 
observation of certain pain-induced changes in the horses’ behaviour. When pain is 
accompanied with stress and fear, behavioural pain assessments may therefore be flawed. 
Long-acting neuroleptics (LANs) have been used empirically to reduce stress during handling 
and transportation of wild animals. Zuclopenthixol acetate (ZUP) is a LAN that has shown 
valuable properties within this area. Acepromazine, a neuroleptic commonly used in horses 
today, has a pronounced sedative effect which is not desirable for long term treatment or for 
observations of behaviour. It would therefore be advantageous if ZUP had the same fear 
reducing effect on horses as in wild animals without sedative acting as acepromazine. Studies 
on the basic pharmacodynamics and pharmacokinetic properties of ZUP have not been 
published for other species than man. Doses and treatment regimens used in wildlife species 
have thus been established entirely on a trail and error basis. The objective of this study was 
to establish a dose of ZUP that would reduce fear or stress in horses, but not induce side 
effects by testing certain pharmacodynamic properties of selected ZUP doses extrapolated 
from earlier wildlife studies. Four horses were included in two dose-range finding pilot 
studies and four other horses were included in a pharmacodynamic study. In the two dose-
range finding pilot studies the horses were given either 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg or 
0.1 mg/kg as a single intramuscular injection of ZUP (Cisordinol-Acutard® or Clopixol-
Acutard®). Based on the findings in the pilot studies, the dose 0.25 mg/kg was used in 
a pharmacodynamic observer blinded, placebo controlled, randomised, cross over designed 
study. That study was conducted in two six-day study sessions with an eight days wash out 
period in between. Fear behaviour was tested via a Novel Object Test (NOT), sedation and 
ataxia was scored using two descriptive scales. These experiments were repeated in 
each study session. Blood sampling was performed for the pharmacokinetic profile 
presented in the thesis of Belfrage (2016). Two horses scored a higher reactivity score 
in the NOT when given placebo compared to ZUP. One of these horses also had a 
slightly elevated sedation score on Day 1 and 3 and showed signs of mild ataxia on Day 3. 
None of the other horses were scored as sedated or ataxic at any occasion. Overall, the 
heartrate elevation was larger in the NOT that was performed in Day 2 compared to Day 4 
each study session (P=0.027) which indicates a habitual effect to the NOT. The effect of 
ZUP seems to be highly individual since there were no noticeable effects in two horses 
administered 0.25 mg/kg, while a third horse had side effects from that same dose. Side 
effects that were documented for doses 0.25 mg/kg, 0.5 mg/kg and 1 mg/kg and 
comprised extrapyramidal symptoms, muscle fasciculations, inappetence, aggressive 
behaviour, tachycardia, colic and submandibular edema. The dose 1 mg/kg was chosen 
because it is recommended for use in several wild life studies including ruminants. No 
empiric recommendations exist for equids. However the dose of 0.25 mg/kg also caused 
some side effects which indicates that horses may be more sensitive to this substance 
than several other species. Since the pharmacodynamic study included only four horses it 
is not possible to draw any valid conclusion about the drugs’ potential anxiolytic effect in 
horses. The substance may though have an anxiolytic or stress reducing effect in horses 
since reduction of fear related behaviour to a quite scary novel object was observed in two out 
of four horses administered 0.25 mg/kg. A safe and at the same time effective dose 
recommendation of ZUP for horses could therefore not be established in this study. Since 
horses have shown high sensitivity to ZUP and the drug has a long acting time, the future use 
of ZUP and the formulations of the drug  should be thoroughly considered when proceeding 
with research. 
SAMMANFATTNING 
Stress är en viktig  homeostatisk funktion som inte enbart är positiv för individen. Studier har 
visat att stress både kan amplifiera och reducera smärta. Smärta kan också inducera stress och 
rädsla. En viktig del av smärtbedömning hos häst är att observera speciella smärtinducerade 
förändringar i hästarnas beteende, men när smärta åtföljs av stress och rädsla kan dessa 
beteendebedömningar bli bristfälliga. Långtidsverkande neuroleptikum (LAN) har använts 
empiriskt för att reducera stress vid hantering och transport av vilda djur. Zuklopentixol acetat 
(ZUP) är ett LAN som har visats ha värdefulla egenskaper inom detta område. Acepromazin, 
ett neuroleptikum som ofta används till häst idag, har en uttalad sederande effekt. Denna 
effekt är dock inte önskvärt vid långtidsbehandling eller vid beteendeobservationer. Det vore 
därför fördelaktigt om ZUP visade samma anxiolytiska effekt hos häst som hos vilda djur utan 
att verka sederande som acepromazin. Studier på ZUPs basala farmakodynamiska och 
farmakokinetiska egenskaper har inte publicerats för andra djurslag än människa. De doser 
som använts vid hantering av vilda djur har enbart fastställts genom “trial and error”.  
Målet med denna studie var att fastställa en dos ZUP som reducerar stress och rädsla hos 
hästar utan att inducera biverkningar genom att testa specifika farmakodynamiska egenskaper 
hos utvalda ZUP-doser, extrapolerade från tidigare studier med vilda djur. Fyra hästar 
inkluderades i två pilotstudier för att finna lämplig dos och fyra andra hästar inkluderades i en 
farmakodynamisk studie. I de två pilotstudierna gavs hästarna antingen 1 mg/kg, 0,5 mg/kg, 
0,25 mg/kg eller 0,1 mg/kg som en enkel intramuskulär injektion av ZUP (Cisordinol-
Acutard® eller Clopixol-Acutard®). Baserat på resultaten från pilotstudien användes dosen 
0,25 mg/kg i en farmakodynamisk observerarblindad, placebokontrollerad, randomiserad, 
cross over-studie. Studien delades upp i två sexdagarssessioner med åtta dagars “wash out” 
mellan. Rädslereaktioner utvärderades med hjälp av ett Novel Object Test (NOT), sedering 
och ataxi bedömdes utifrån två deskriptiva skalor. Dessa experiment upprepades under varje 
studiesession. Blodprover togs för att få fram en farmakokinetisk profil som presenteras i en 
uppsats av Belfrage (2016). 
Två hästar bedömdes ha en högre reaktionsgrad vid NOT då de administrerats placebo 
jämfort med ZUP. En av dessa hästar bedömdes också milt sederad dag 1 och dag 3 och 
visade tecken på mild ataxi dag 3. Ingen av de andra hästarna bedömdes vara sederade eller 
visa tecken på ataxi vid något tillfälle. Hjärtfrekvensstegringen var generellt högre i det NOT 
som utfördes dag 2 jämfört med dag 4 i båda studiesessionerna (P=0,027), vilket indikerar en 
habitueringseffekt. Doseringen verkar vara mycket individuell då två hästar inte uppvisade 
någon effekt av 0,25 mg/kg, medan en annan fick biverkningar av samma dos. Biverkningar 
dokumenterades vid administrarion av doserna 0,25 mg/kg, 0,5 mg/kg och 1 mg/kg och 
innefattade extrapyramidala symptom, muskelfascikulationer, inappetens, aggressivitet, 
takykardi, kolik och submandibulärt ödem. Dosen 1 mg/kg valdes då den rekommenderas i 
flera studier med vilda djur inklusive idisslare. Inga empiriska rekommendationer finns för 
hästdjur. Dosen på 0,25 mg/kg gav, som tidigare nämnts, också upphov till biverkningar 
vilket indikerar att häst är mer känslig mot substansen än flera andra djurslag. Eftersom den 
farmakodynamiska studien endast inkluderade en population av fyra hästar försvårar det 
möjligheten att dra några slutsatser kring substansens potentiella anxiolytiska effekt hos häst. 
Substansen kan dock ha en anxiolytisk eller stressreducerande effekt hos hästar då reduktion 
av  rädslerelaterat beteende mot ett skrämmande föremål observerades hos två av fyra hästar 
doserade 0,25mg/kg. En säker och samtidigt effektiv dos kunde inte fastställas i den här 
studien och hästarna har uppvisat hög känslighet för substansen, vilket bör tas i noga 
beaktning vid eventuellt fortskridande av denna forskning. 
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INTRODUCTION 
“The stress response represents an animal’s attempt to reestablish the body’s homeostasis 
after injury, intense physical activity, or psychological strain.” (Wagner, 2010). Studies have 
shown that stress has the ability to both inhibit and enhance pain (Jennings et al., 2014; Butler 
& Finn, 2009). It is suggested that different types of stressors has this property, where anxiety 
is thought to increase pain and acute stress is linked to inhibiting pain (Rhudy & Meagher, 
2000). It can be difficult to distinguish anxiety from fear since they are overlapping states. 
Fear is usually defined as being induced by a direct threat and anxiety by an expectation of a 
threat (Öhman, 2008). Stress is an important bodily function to prepare the body for fight or 
flight and its acute pain inhibiting function may help an injured animal escape a predator 
despite injury.  
 
Due to rapid and complex biological responses stress is difficult to measure outside the 
laboratory (Moberg, 1987). Since horses are prey animals they often mask their pain (Weary 
et al., 2009). Stress may also mask horses’ pain behaviour, thus making it more difficult for 
veterinarians to detect and treat pain (Lerche, 2009). It is therefore important to evaluate and 
manage stress in painful or potentially painful situations.  
 
Under certain circumstances, for example under hospitalisation procedures and espescially 
during pain research, it would therefore be desirable to inhibit/modulate horses’ anxiety. This 
modulation should, however, not act sedating or impair the horses’ behaviour or ability to 
perform basic needs such as eating and drinking. If the anxiety of a horse could be reduced 
without the induction of sedation, behaviourally based assessments of for example pain 
probably would be more accurate.  
 
To decrease stress when handling and transporting wild animals the long-acting neuroleptic 
zuclopenthixol acetate (ZUP) has been used empirically and been found to have valuable 
properties (Read & McCorkell, 2002; Read et al., 2000; Holz & Barnett, 1996). Treated 
animals were easier to handle, showed less increase in physiological parameters indicating 
stress and acclimatized faster to their new environment. Acepromazine, a neurolept drug 
commonly used in horses today, has a pronounced sedative effect which is not desirable for 
long term treatment and the sedated behaviour hampers pain assessment and the use of a 
neurolept drug with less sedative effect is therefore warranted. However, no studies on the 
basic properties of ZUP have been published for other species than man. Doses for use in 
wildlife species have been established entirely on an empiric basis, as have a significant part 
of the estimations of the wild animals body weight. Reports of both wanted and adverse 
effects from these wildlife field studies could thus be suspected to be inaccurate and, given 
the circumstances in the field, also sparse. Therefore, the overall aim of this study was to 
investigate clinically relevant pharmacodynamic properties of ZUP in horses. The research 
questions were: which ZUP doses are relevant and safe for horses, whether ZUP has the 
ability to reduce fear of a novel and frightening object and whether ZUP has sedative 
properties, including ataxia, or other unwanted effects.  
 
The hypotheses of the study were that doses of ZUP relevant for horses were comparable to 
those in wildlife and that such ZUP doses would reduce behaviour indicative of fear without 
inducing ataxia or side effects. The objective of the study was to test different doses of ZUP 
in horses, extrapolated from earlier wildlife studies, to establish a relevant anxiolytic dose that 
2 
would not induce side effects and use this dose to perform a pharmacodynamics study in four 
horses.  
 
The study was conducted as two dose-range finding pilot studies with four horses and an 
observer-blinded placebo controlled randomised cross over study of four other horses during 
two six-day periods. Fear behaviour was tested via a Novel Object Test (NOT), sedation and 
ataxia was scored using two descriptive scales. 
 
This study was performed simultaneously with the study of pharmacokinetic properties of 
ZUP (Belfrage, 2016), Parts of the Material and Methods section will therefore be similar 
between these two studies. Also pharmacokinetic data was made available and will 
followingly be cited where relevant.  
 
LITERATURE REVIEW 
Zuclopenthixol acetate 
ZUP is a neuroleptic in the thioxantene class. The effect is probably exerted mainly by 
blocking Dopamine receptors (Jayakody et al., 2012). The formulation of Cisordinol-
Acutard® and Clopixol-Acutard®, used in this study, is oil based and thus providing a slow 
release of the substance and is effective from one to three days. The formulation is considered 
very tissue friendly.  
 
ZUP is used for schizophrenia and to reduce psychoses in human medicine. As it has 
anxiolytic properties it is also used in veterinary medicine, mainly when translocating and 
handling wild ungulates. In this area, it has been shown to have advantageous properties. 
Treated animals have shown less incidents of captive myopathy, been easier to handle and 
have acclimatized faster to their new environment  (Read & McCorkell, 2002; Read et al., 
2000; Holz & Barnett, 1996). However, the drug has not shown the same positive qualities in 
all species. In cheetahs, side effects such as ataxia, inappetence, akathisia and extrapyramidal 
reactions were seen and the authors therefore concluded that zuclopenthixol acetate was not to 
be used for cheetahs (Huber et al., 2001).  
 
The doses have varied widely among different species, several wildlife studies in ungulates 
present desirable effects of 1 mg/kg ZUP (Read & McCorkell, 2002; Read et al., 2000; 
Diverio et al., 1996). In another study red necked wallabies were treated with up to 15 mg/kg 
with no observed side effects (Holz & Barnett, 1996).  Recommended dosing for human 
varies between 50 and 150 mg per person (Lundbeck, 2011). The substance has not 
previously been tested in equides. 
 
Stress and pain in horses  
The International Association for the Study of Pain (IASP) define pain as “An unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage.” (IASP, 2012). Pain is an individual experience and 
studies have shown that the presence of stress both can inhibit pain, so called “stress-induced 
analgesia”, and enhance pain, also known as “stress-induced hyperalgesia” (Jennings et al., 
2014; Butler & Finn, 2009). A study of Marntell et al. (2006) showed that horses castrated in 
a foreign environment (in an animal hospital) needed more anaesthetics than horses who 
underwent the same surgical procedure in its home environment.  
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When an animal is exposed to a stressful situation the sympathetic nervous system together 
with the endocrine system prepares the animal for an emergency. This leads to increased 
excretion of epinephrine and norepinephrine, increased heart rate, vasoconstriction, reduced 
motility of intestines, dilation of bronchioles, pupil dilation amongst other things. During 
stress corticotrophin-releasing hormone (CRH) is also released, which makes the 
hypothalamus release ACTH. This in turn causes the adrenal cortex to release glucocorticoids 
such as cortisol (Sjaastad et al., 2010b; Sjaastad et al., 2010a). This reaction is also called the 
“hypothalamic pituitary adrenocortical axis” or HPA-axis. This axis is often the focus when 
measuring stress, although it is important to not only investigate this parameter since the 
response is more complex (Novak et al., 2013).  
 
Physiological parameters used to measure both stress and pain in horses are for instance beta-
endorphin, cortisol, heart rate, abdominal sounds and catecholamines (dopamine, adrenaline, 
noradrenaline) (Raekallio et al., 1997). Since several of the physiological parameters 
mentioned above increase in both stressful and painful situations it is also important to 
observe the horses’ behaviour to separate the two states. Behaviours that indicate pain are for 
instance: head-lowering, flaring of nostrils, kicking towards the abdomen, aggression, 
pawing, sweating, flight behaviours, restlessness, rolling, reluctance to be handled, teeth-
grinding and rigid posture (Bufalari et al., 2007; Raekallio et al., 1997). Another way to 
evaluate pain in horses is by observing their facial expressions (Gleerup et al., 2015).  
 
Behavioural analysis 
In order to measure, compare and quantify horses' behaviour and temperamental traits in a 
standardized manner, one can use a so-called Novel Object Test (Visser et al., 2001).  The 
Novel Object Test (NOT) is a behavioural test used in several species including horses. The 
test involves exposing the animal to a novel, objectively harmless, but frightening object, 
whereupon the animals’ reactions are observed. This test has for instance been used as an 
objective tool to describe horses’ “personalities” (Visser et al., 2001). This test has also been 
used in a study similar to this where the behavioural effects of L-tryptophan in horses was 
investigated (Noble et al., 2008). 
 
Several different objects have been used as novel objects and some objects tend to be more 
frightening than others (Bulens et al., 2015). The horses also appeared to react more to some 
colors than others (Christensen et al., 2008; Hall & Cassaday, 2006).  
 
To make the NOT more accurate, several previous studies have habituated the horses by 
accustom them to the test arena and handling/testing procedure without performing the actual 
NOT before the test (Christensen et al., 2005).  
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MATERIAL AND METHODS 
This study was approved by the Ethical Committee for Experimentation with Animals, 
Uppsala, Sweden. 
 
Dose range finding studies 
Two dose range-finding pilot studies were performed. The pilot studies included four 
warmblooded trotters, one gelding and three mares, aged 4, 5, 5 and 6 years. Based on earlier 
studies two horses were dosed either 1 mg/kg or 0.5 mg/kg of ZUP (Cisordinol-Acutard® or 
Clopixol-Acutard®, 50 mg/ml) intramuscular in the neck (Read & McCorkell, 2002; Read et 
al., 2000; Diverio et al., 1996). Blood was collected for analysis of ZUP concentration, 
according to expected pharmacokinetic data from the jugular vein. On the basis of these data a 
second study was performed where two other horses were dosed either 0.25 mg/kg or 0.1 
mg/kg and blood sampling schemes were adjusted. Different types of NOT were conducted in 
order to establish the most reliable method for the pharmacodynamic study.  
 
Study design of the pharmacodynamic study 
Four horses were included in an observer blinded, placebo controlled, randomised, cross over 
designed study. Each horse was dosed either ZUP or saline in the same volume as it would 
have been if given ZUP in the first session, and the opposite in the second session  (see Table 
1). The substances were given as a intramuscular injection in the neck on the opposite side of 
the permanent cannula (see below) by a veterinarian otherwise unrelated to the project and 
without presence of the research students. 
 
Table 1. Order in which the horses were given ZUP and placebo respectively.  
 Study session 1 Study session 2 
Horse 1 ZUP Placebo 
Horse 2 Placebo ZUP 
Horse 3 Placebo ZUP 
Horse 4 ZUP Placebo 
 
Animals, housing, handling and management 
Included in this study were two warmblooded trotters, a gelding aged 2 and a mare aged 11, 
one “Svensk Ridponny” gelding aged 23 and one Swedish warmblood mare aged 25. The 
horses belonged to the Swedish University of Agricultural Sciences (SLU) teaching herd, and 
were housed and cared for at SLU according to the guidelines for horse keeping 
(Jordbruksverket, 2014). They were stabled on shavings in individual loose boxes in a 
compartment of the stable, separated from the other part of the teaching herd stables. The 
horses were let out during the day (except on Day 1 each study session) approximately 
between 07.00 and 15.00 hours. The horses were fed grass hay four times a day, water ad 
libitum and a small amount of soaked sugar beet with some paraffin oil between Day 1 and 
Day 4 to 5 each study session to avoid constipation. Each box was equipped with a salt lick.  
The experiments were carried out between 17 October 2015 and 11 November 2015. One day 
before the first injection a complete clinical examination was performed and all clinical 
findings were noted. Daily from Day 1 (day of injection) to Day 7 general condition, heart 
rate, respiratory rate, capillary refill time, appearance of oral mucosa, temperature and bowel 
sounds (right dorsal and ventral and left dorsal and ventral) were noted.  
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Blood sampling 
A permanent cannula was inserted in the right jugular vein (first study session) or left jugular 
vein (second study session) prior injection of the substance and was used for blood sampling 
within the first 24 hours. After removing the permanent cannula a Vacutainer® with a 20 G 
needle was used. Blood sampling was performed at 0 hours (just before injection of substance 
or placebo) and at 2, 4, 8, 16, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post injection 
using Vacuette® EDTA tubes. After blood sampling, the tubes were immediately centrifuged 
at 3000 rpm for 10 minutes and the EDTA plasma was then separated and collected in a Cryo 
TubeTM or Sarstedt micro tubes. The EDTA plasma was frozen to -20 degrees C immediately 
after centrifugation.   
 
When all blood samples had been collected the tubes were transported in a Styrofoam box at  
-20 degrees C to Lundbeck A/S, Copenhagen, Denmark, for analysis. These data are reported 
in a thesis of Belfrage (2016).  
 
Novel object test (NOT) 
Test arena 
The NOTs were performed in the indoor riding arena of SLU, located approximately 200 
meters from the stables where the horses were kept. The riding arena measured 27 x 21 
meters with 2.2 meter high walls. The underlay of the arena consisted of sand and small 
gravel. The colour of the underlay was brown/beige and the arena was illuminated by strip 
light during the tests. 
 
The novel object consisted of a radio-controlled electric car (Vortex A969 Truck RTR 
2.4GHz) measuring 29 x 17 x 6 cm with the body wrapped in black self-adhesive bandage to 
give it a uniform colour. On top of the car two balloons of the same colour, measuring 
approximately 25 cm in height and 18 cm in width, were attached. They stood for the overall 
impression of the novel object (see Figure 1). The car was connected to different corners of 
the arena every NOT by a 3-meter string with a shock absorber made out of a Penrose drain 
(elastic string) in the end to ensure the same travel distance in all NOTs. The top speed of the 
car was 40 km/h. The RC-car had a distinct motor sound.  
 
 
Figure 1. RC-car with balloons used as novel object. 
Three dummies mimicking the car were made out of test tube racks, wrapped in the same self-
adhesive bandage measuring 25 x 15 x 5 cm, see figure 2. The dummies were also equipped 
with two balloons each, with the same size as those attached to the car. The colours of the 
balloons were green, blue, yellow and pink/red.  
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Figure 2. Dummy mimicking the novel object. 
In each corner (below named 1, 2, 3, 4) of the testing arena, the novel object (RC-car) or a 
dummy was placed 50 cm from the wall. Between each NOT session both the colour of the 
balloons in respective corner, and in which corner the novel object was placed, was changed 
(see Table 2). The setup for the first NOT session was randomly selected and the following 
setups were balanced. 
 
Table 2. The colour of the balloons attached to the dummies and the RC-car relative to the 
corners. The colour of the balloons on the RC-car followed by “*” which indicates from 
which corner the RC-car is coming from in each NOT. 
 Corner 1 Corner 2 Corner 3 Corner 4 
Novel object test 1 Pink/Red Blue Green* Yellow 
Novel object test 2 Yellow* Green Blue Pink/Red 
Novel object test 3 Blue Pink/Red* Yellow Green 
Novel object test 4 Green Yellow Pink/Red Blue* 
 
In the middle of the arena, 17 m from the corners, a bucket with oats was placed. Figure 3 
shows a sketch of the arena.  
 
 
Figure 3. Sketch of the test arena. The model with the blue balloons symbolizes the RC-car in 
its original position and with its end position marked. The other models with balloons 
symbolize the dummies. The food bucket is marked in the middle. The sketch is not made to 
scale.  
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Testing procedure 
Prior to the testing, the horses were habituated to the test arena at least two times the two days 
before the test. The habituation consisted of leading the horse two laps around the arena and 
then letting it eat oats from the food bucket for a couple of seconds. After that the horse was 
led a few meters from the bucket and released. The handler then stepped out of the arena. The 
horse was left loose in the arena for maximum ten minutes or until the habituation criteria, 
which was: eating continuously from the food bucket for minimum 20 seconds, was met. The 
habituation procedure was adapted from Christensen et al. (2005). All horses met the 
habituation criteria before the NOT was conducted. 
 
Heart rate was measured by a Polar RCX3, an electrode belt (see Figure 4) transmitting to a 
wrist-watch receiver attached to the halter. The data was stored in the receiver and later 
transferred to a computer by Polar DataLink. Before the NOT the pulse imaging equipment 
was attached to the horse inside the stable. The heart rate was recorded during walking to the 
arena and as the horse was released the handler started a new lap on the monitor to mark this 
time and relate it to the heart rate during the NOT. During the habituation process the horses 
wore the pulse imaging equipment once. 
 
 
Figure 4. Horse equipped with the electrode belt for pulse imaging. 
The NOT was performed in the arena at Day 2 and Day 4 of each study session, 30-31.5 and 
78-79.5 hours post injection, respectively. Thus each horse was subjected to the NOT a total 
of four times. Before the horse was released the habituation procedure was performed.  The 
handler then stepped out of the arena. While the horse ate from the food bucket the RC-car 
was run towards the horse in full speed to the end of the attached string (3 meters).  
The NOT was video recorded by a Go Pro® Hero 3+. To synchronize the recordings the 
observer started the video recording at the same time as the handler started a new lap on the 
pulse monitor. The videos were cut in a videoediting program (iMovie®) to show 19-48 
seconds of the NOT and the clips were then blinded and randomized for the observers. The 
horses’ reactions were later classified by the observers Linda Keeling (professor at the 
department of Animal Environment and Health, SLU) and Karina B Gleerup (DVM, Ph.d., 
Assistant Professor, University of Copenhagen), using a protocol adapted from von Borstel et 
al. (2010) and Christensen et al. (2006) (see Table 3). 
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Table 3. Reactivity scores used to classify the horses’ reaction during the NOT. 
Score Reaction 
0 None. The horse may or may not direct its attention (turn ear and/or eye) to the 
stimulus but does not stop eating/chewing or lift the head in response to the stimulus. 
1 Head up. The horse throws its head up, stops eating but does not move away. 
2 Alert. The horse quivers and may take up to five steps away from stimulus.  
3 Away. The horse jumps to the side or back and trots or gallops away for more than 
five but less than ten strides. 
4 Flight. The horse jumps to the side and or back and gallops or trots for more than ten 
but less than fifteen strides.  
5 Run off. The horse jumps to the side and or back and gallops or trots for more than 
fifteen strides.  
 
The time before the horse returned to feeding after the appearance of the Novel Object was 
noted. The test ended either when the horse returned to feeding or when the horses had been 
inside the arena for a maximum of 10 minutes. If a horse did not return to feeding within the 
maximum time the time was set to 60 seconds. 
 
 
Figure 5. Horse eating from the food bucket in the NOT. 
 
 
Figure 6. Horse reacting on the novel object which is marked with an arrow. 
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Sedation scoring and head position in stable  
On Day 1 and 3 at 16.30-17.30 hours, which correspond to 5.5 – 6.5 and 53.5 – 54.5 hours 
post injection, respectively, the horses were video recorded using a Canon Ixus digital pocket 
camera in their boxes. Before each video session the horses’ compartment of the stable was 
left quiet for a minimum of 30 minutes.   
 
The horses were filmed for a minimum of 3 minutes at each occasion. The session started by 
filming the horse from a distance, if possible without disturbing the horse. The horse was then 
approached and its face filmed in profile and from an approximately 60-degree oblique angle 
visualizing both nostrils from a short distance. After that the observer interacted with the 
horse and presented with a bucket of oats. The assessment of depth of sedation was performed 
directly by the author and later by Pia Haubro Andersen (professor at the department of 
Clinical Sciences, SLU) based on a sedation scale used by Taylor et al. (2014), see Table 4.   
 
Table 4. Scoring system for sedation. 
Score Signs 
0 No sedation. Animal is alert, with normal posture and response to contact with assessor. 
1 Mild sedation. Low head carriage, relaxed facial muscles and pendulous lower lip. 
2 Moderate sedation. Head lowered towards ground and swaying of hind legs. 
3 Marked sedation. Nearly becomes, or becomes, recumbent. 
 
While filming, if possible before the horse was disturbed, its head position was noted and 
scored by the author while video recording and later the clips were evaluated by Pia Haubro 
Andersen according to Table 5.  
 
Table 5. Scoring system for head position. 
Score Position of muzzle 
0 Muzzle above shoulder. 
1 Muzzle between shoulder and carpus. 
2 Muzzle between carpus and fetlock. 
3 Muzzle below fetlock. 
 
Ataxia scoring 
To detect any ataxia the horses were led both up and down a curb four times and in figure of 
eights for four times. These gait assessment tasks were adapted from Olsen et al., 2014. This 
test was performed at Day 1, 3 and 6 at 17.00-18.00 hours, which corresponds to 6-7, 54-55 
and 126-127 hours post injection. Ataxia was assessed directly by one of the research students 
according to Table 6. 
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Table 6. Scoring system for ataxia. 
Score Degree of ataxia 
0 No ataxia. The horse stands and walks normally; is able to turn tightly. 
1 Mild ataxia. The horse is able to walk, but has some lack of limb control. 
2 Moderate to marked ataxia. The horse can walk only with support or is unable to 
walk without danger of falling. 
  
Statistical analysis 
No statistical analysis was performed on the pilot studies. In the pharmacodynamic study all 
data were entered in an Excel® sheet and descriptive graphs and tables were made of raw data, 
where possible. Minitab® 17 statistical software was used for statistical analysis.  
 
From the Polar data sheet, the heart rate when the novel object appeared (HR1) and the first 
turning point (peak or bottom) after the appearance of the novel object (HR2) was extracted. 
See Table 7. 
 
Table 7. Polar data sheet showing heart rate when walking to arena and during NOT. HR1 
and HR2 are marked with circles.  
 
 
The following hypotheses were tested:  
• Is the difference between HR1 and HR2 smaller when given ZUP instead of placebo? 
• Do the horses, when given ZUP, return to feeding faster than when given placebo?  
• Do the horses score a lower reaction-score when given ZUP instead of placebo?  
The above-mentioned hypotheses were also tested including only the first NOT conducted 
each study session (NOT 1 and 3) and by comparing NOT 1 and 3 to NOT 2 and 4.  
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RESULTS 
Novel object test 
The scorings made of both evaluators are presented in Table 8 and the evaluators are named 
Evaluator 1 and 2. 
 
Table 8. Scorings NOT. E1 = Evaluator 1, E2 = Evaluator 2. *Treated with ZUP. 
Study 
session 
Day of 
NOT NOT score 
  
Horse 1 Horse 2 Horse 3 Horse 4 
E1 E2 E1 E2 E1 E2 E1 E2 
1 
2 3* 5* 3 4 5 5 1* 1* 
4 2* 3* 2 2 1 1 1* 1* 
2 
2 3 3 1* 1* 3* 5* 3 5 
4 1 1 0* 3* 3* 5* 2 2 
 
The heart rate when the novel object appeared (HR1) and the first turning point (peak or 
bottom) after the appearance of the novel object (HR2) for each horse and NOT are presented 
in Table 9. 
 
Table 9. HR1 and HR2 in each NOT for each horse. N = Novel Object Test, Z= ZUP, 
P=Placebo, H=horse. 
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The difference between HR1 and HR2 for each horse and NOT are presented in Table 10.  
 
Table 10. Difference between HR1 and HR2 in each NOT for each horse. N = Novel Object 
Test, Z= ZUP, P=Placebo, H=horse. 
 
 
Time before the horse returned to feeding after the appearance of the Novel Object is 
presented in Table 11. On three occasions (in NOT 1, 3 and 4) Horse 3 did not return to 
feeding within the maximum time and the time was therefore set to 60 seconds. 
 
Table 11. Time to return to feeding in each NOT for each horse. N = Novel Object Test, Z= 
ZUPl, P=Placebo, H=horse. 
 
 
 
 
 
 
 
 
 
 
 
 
-20 
0 
20 
40 
60 
80 
100 
N1 N2 N3 N4 N3 N4 N1 N2 N3 N4 N1 N2 N1 N2 N3 N4 
Z Z Z Z Z Z Z Z P P P P P P P P 
H1 H1 H2 H2 H3 H3 H4 H4 H1 H1 H2 H2 H3 H3 H4 H4 
hr
 (b
pm
) 
0 
10 
20 
30 
40 
50 
60 
70 
N1 N2 N3 N4 N3 N4 N1 N2 N3 N4 N1 N2 N1 N2 N3 N4 
Z Z Z Z Z Z Z Z P P P P P P P P 
H1 H1 H2 H2 H3 H3 H4 H4 H1 H1 H2 H2 H3 H3 H4 H4 
tim
e 
(s
ec
) 
13 
The difference between HR1 and HR2 for each horse in NOT 1 and 3 are presented in Table 
12. 
 
Table 12. Difference between HR1 and HR2 in NOT 1 and 3 for each horse. N = Novel 
Object Test, Z= Zuclopenthixol, P=Placebo, H=horse. 
 
 
There were no significant differences between ZUP and placebo in any of the tested 
parameters. The difference between HR1 and HR2 were significantly greater in NOT 1 and 3 
compared to NOT 2 and 4 (P=0,027, paired t-test).   
 
Sedation scoring 
The sedation and head position scores are shown in Table 13 and 14. One horse (Horse 4) was 
rated as mildly sedated and had a lower head position (muzzle between shoulder and carpus) 
on Day 1 and Day 3 when given ZUP.  
 
Table 13. Sedation score. *Treated with ZUP. 
Study session Day of 
scoring Sedation score 
  Horse 1 Horse 2 Horse 3 Horse 4 
1 
1 0* 0 0 1* 
3 0* 0 0 1* 
2 
1 0 0* 0* 0 
3 0 0* 0* 0 
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Table 14. Head position score. *Treated with ZUP. 
Study session Day of 
scoring Head position score 
  Horse 1 Horse 2 Horse 3 Horse 4 
1 
1 0* 0 0 1* 
3 0* 0 0 1* 
2 
1 0 0* 0* 0 
3 0 0* 0* 0 
 
Ataxia scoring 
Ataxia scores of all horses are shown in Table 15. One horse had mild ataxia on Day 3, two 
days post injection.  
 
Table 15. Ataxia scores. *Treated with ZUP. 
Study 
session 
Day of 
scoring Ataxia score 
  Horse 1 Horse 2 Horse 3 Horse 4 
1 
1 0* 0 0 0* 
3 0* 0 0 1* 
6 0* 0 0 0* 
2 
1 0 0* 0* 0 
3 0 0* 0* 0 
6 0 0* 0* 0 
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Pharmacokinetics 
The plasma concentration of ZUP was about twice as high when performing the NOT on Day 
2 (NOT 1/3) compared to Day 4 (NOT 2/4), see Table 16. The pharmacokinetics of the study 
are investigated in the thesis of Belfrage (2016).  
 
Table 16. Time of NOT relative to plasma concentration in all horses. H=horse. 
 
 
Side effects 
One horse given 1 mg/kg obtained severe extrapyramidal symptoms including rhythmic head 
tossing in a snakelike manner, pawing, compulsive circling, sweating, backing up against the 
walls and kneeling on both carpi. This horse also developed intermittent tachycardia, muscle 
fascicualtions, edema in the submandibular area and later signs of colic. 
 
Another horse given 0.25 mg/kg also presented with colic symptoms and was diagnosed with 
constipation in flexura pelvina. Muscle fasciculations were also seen in another horse given 
0.25 mg/kg.  
 
Two horses, one given 0.5 mg/kg and one given 0.25 mg/kg showed aggressive behaviour 
towards humans when handled. One horse given 0.25 mg/kg became mildly inappetent. No 
adverse tissue reaction at the injection site were seen. 
 
Other observations 
One horse included in the pilot study, who was given 1 mg/kg, resented (mostly by powerful 
attempts to escape) when handling its permanent cannula during blood sampling before and 
just after the injection of ZUP. At the second blood sampling, 4 hours post injection, and 
henceforth the horse stood completely still when handling its permanent cannula.  
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DISCUSSION 
This study aimed to investigate wether ZUP decreases fear and anxiety in horses. As fear and 
anxiety are emotions which cannot be communicated directly between man and horse, current 
knowledge of horses behaviour and reaction to frightening experiences was used to design 
test systems that could be used for this. Parameters that were used was: elevation of heart rate, 
time to return to feed and reaction to a novel object. Since only four horses were included in 
the study, statistically validated conclusions could not be drawn. Therefore this study should 
be regarded as an initial pilot study. In the following, the performance of the above mentioned 
methods will be discussed.  
 
Novel object test 
Reduction of fear related behaviour was observed in two out of four horses administered 0.25 
mg/kg. One of these horses was scored as less reactive on the NOT in the first study session, 
when treated, compared to the second study session when given placebo, indicating that 
despite any habitual effect to the NOT ZUP did seem to have an anxiolytic or stress reducing 
effect in some horses. The plasma concentration of ZUP was about twice as high when 
performing NOT on Day 2 (NOT 1/3) compared to Day 4 (NOT 2/4). Therefore the test 
values from NOT 1 and 3 were analysed separately. 
 
A habitubal effect to the NOT was demonstrated as a significantly greater difference between 
HR1 and HR2 in the NOT performed Day 2 (NOT 1/3) compared to Day 4 (NOT 2/4). 
Habituation may hamper this test and to reduce the habitual effect, the spatial location of the 
moving object (corner from which the novel object came from), and the colour of the balloons 
attached to the moving object, was varied in a balanced matter for each NOT. The colours 
used for the balloons in the NOT were green, blue, yellow and pink/red. As previously shown 
by Smith & Goldman (1999) horses can discriminate these colours from grey. To avoid the 
habitual effect completely the NOT should have been performed only once but then the horses 
could not have been their own controls. Without the horses being their own control such a 
small number of horses would carry the risk to not give any relevant information since the 
horses’ reactions to the NOT are highly individual (Visser et al., 2001). Another alternative 
would have been to include a large number of horses and treat half of them with ZUP and the 
other half with placebo before the NOT. In that way the individual variation would become 
less significant and the effect of habituation could have been ruled out.  
 
It is important to note that this study only included measuring heartrate elevation and 
behavioral parameters. There is, as mentioned above, several other parameters to measure 
stress that could be used to gather more information. At the same time, taking for example 
blood samples at the time of NOT could be stressful in itself and therefore bias the results. 
 
To avoid “novelty effect” of the surroundings and thus make the NOT more specific, the 
horses were habituated to the arena with all the equipment needed for the NOT. The 
habituation procedure was repeated until the horse could stand still and focus on eating for 20 
seconds. In this way the only novel object was the moving RC-car and not the entire arena. 
Besides the habitual effect the practical performance of the NOT worked well and the horses 
displayed large variation in reactivity both between individuals and test sessions. Another 
novel object that was tested in the pilot study, an umbrella lowered from the ceiling (also used 
in Visser et al. (2002) and Visser et al. (2001)), barely caused any observable reaction in any 
of the horses and was therefore not suitable for this study. The fact that the novel object used 
in this study differed quite a lot from the novel objects used in several previous studies and 
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also made sounds makes the results less comparable to these studies although the principle is 
the same.  
 
The scorings of the NOTs were consistent between the evaluators in most cases though one 
evaluator systematically scored the reactions lower than the other. This may be due to lack of 
sufficiently clear instructions, borderline cases, subjective definitions of what counts as a step 
or difficulty to count the amount of steps. The ethogram used had been proven useful in other 
studies (von Borstel et al., 2010; Christensen et al., 2006).  
 
Ataxia and sedation 
In contrast to the NOT scoring there was a high degree of agreement between the raters of 
ataxia, probably due to the simplicity of the scale. One out of four horses became mildly 
ataxic two days post injection. Ataxia was also seen as a side effect in cheetahs treated with 
ZUP (Huber et al., 2001). The same horse was also assessed as mildly sedated on Day 1 and 
3. This means that sedation can not be ruled out as a side effect of a first dose of ZUP. In 
humans, sedation is reported as a side effect during the first doses of ZUP, and the sedative 
effects then resides with subsequent doses (FASS, 2014). We did not test further doses and 
whether sedation would disappear with repeated dosing in horses is therefore not known.  
 
Establishment of a relevant dose of ZUP 
A ZUP dose which was safe and clinically effective for all horses could not be established in 
this study. The fact that the dose of 0.25 mg/kg gave no noticeable fear reducing effect in two 
horses and side effects in a third horse indicates that the effect may be highly individual. This 
is surprising since the drug has been used extensively during the last 30 years for wild life 
handling. The recommended dose varies considerably depending on the species. Horses thus 
seem much more sensitive to the side effects of ZUP than other species, and this is important 
to note before any further use of the drug is initiated. Parallels to such species differences is 
also seen in other drugs, for example the α2 antagonist xylazine where cattle doses are around 
10% of effective horse doses (Greene & Thurmon, 1988). Since both the horses in this study 
and the cheetahs in the study of Huber et al. (2001) were sensitive to the substance this 
species variation should be considered in further research of the substance in other species. 
The reason for this species differences can only be speculative, but dopamine receptor 
profiles, numbers of receptors and the neuroanatomy of the extrapyramidal system may be 
involved.  
 
As mentioned above fear is usually defined as being induced by a direct threat and anxiety by 
an expectation of a threat (Öhman, 2008). Since the novel object is perceived as a threat the 
NOT causes fear. The NOT was performed four times with each horse in this study and 
therefore the horses may have had an expectation of the threat the last three times and due to 
that they may have felt anxious as well. As a consequence this study has the potential to 
induce both fear and anxiety. It would therefore be interesting to design a study focusing only 
on whether the substance reduces anxiety since this mainly is thought to amplify pain 
sensation. It is though difficult to determine what kind of stress an animal is experiencing.  
 
Side effects 
The extrapyramidal adverse signs seen in one of the horses from the pilot study were very 
similar to the side effects described in horses treated with the neuroleptic fluphenazine 
decanoate (Baird et al., 2006). Extrapyramidal signs have been observed in humans and 
white-tailed deer treated with zuclopenthixol acetate (Hassler et al., 2014; Read & McCorkell, 
2002).  
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Since two horses in the pilot studies presented with obstipation of the large colon all horses in 
the pharmacodynamic study were prophylactically administered oral paraffin oil together with 
soaked sugar beet once a day from Day 1 to Day 4-5 of each study session. The concrete 
reason for the colic is not known but the horses had been subjected to several colic 
predisposing factors such as relocation, change of forage, feeding routines etcetera before this 
study and it is therefore not possible to determine whether  or not the substance was the cause 
of colic (Cohen et al., 1999). However, constipation is listed among common human side 
effects, though as a long term effect (FASS, 2014). One disadvantage of the slow release drug 
formulation is that it can not be reversed if side effects appear. The formulation in visceo oil 
was therefore not suited for this research purpose. The formula is otherwise advantageous 
since it reduces the number of injections. The side effects are discussed more in detail in the 
thesis of Belfrage (2016). 
 
Aggression 
In this study two horses showed aggession towards humans during handling at the time of 
peaking blood concentrations. The theories behind the causes of this are obscure but 
interesting. Most horses today are trained with negative reinforcement (McGreevy & 
McLean, 2011). A study by Sankey et al. (2010) showed that horses trained with negative 
reinforcement instead of positive reinforcement sought less contact with humans and showed 
“an increased emotional state” during training. Wildlife studies suggest that the animals 
treated with ZUP became less afraid of humans than the controls (Read & McCorkell, 2002; 
Read et al., 2000; Holz & Barnett, 1996). We speculate if it is possible that the reason for this 
aggression is of a similar manner as seen in these wildlife studies. Could aggression be a form 
of expression for a loss of boundaries set by training with negative reinforcement? Aggressive 
behaviour has also been observed in dogs treated with ZUP during research. The dogs were 
usually kept two and two in cages but had to be separated due to fighting during the treatment 
of ZUP (Höjelse, 2016).  
 
Ethics  
Since it is impossible to know exactly how an animal perceives its surroundings, it is likewise 
problematic and difficult to evaluate the possible effect of a drug that may act through change 
of perception. If the drug would reduce fear and anxiety during unpleasant situations of horses 
animal welfare might eventhough be increased. One can speculate whether the altered 
perception was experienced as unpleasant. No reports of unpleasant body feelings have been 
reported from the use in humans with psychosis. Since the horses were healthy and seemed 
much more sensitive to the drug, this information may not be valid for horses. Two horses in 
this study were reluctant to enter their boxes the days following the injection of ZUP but not 
before or after treatment. This may indicate that ZUP in these doses inflicted discomfort in 
these horses, though the extent of the negative aspects of these experiences remain uncertain. 
With this in mind more research is needed in this area and it is crucial that the risks and 
benefits of using these drugs are carefully analysed to ensure that the positive aspects 
outweigh the negatives. The use of ZUP may be of interest in relation to research, for example 
in pain research when elimination of  stress related behaviour is needed, but other drug 
formulations that allowed rapid adjustment of the dose would be preferrable to aviod side 
effects.  
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CONCLUSION 
The response to ZUP seems to be highly individual and horses seem to be far more sensitive 
to the drug than other species. The doses 0.5 and 1 mg/kg gave rise to moderate and severe 
side effects in two horses. A dose of 0.25 mg/kg caused mild side effects in one out of four 
horses. A dose of 0.1 mg/kg did not have any observable effect in one horse. ZUP did not 
give rise to pronounced ataxia or sedation in the dose 0.25 mg/kg. The substance may have an 
anxiolytic or stress reducing effect in horses since reduction of fear related behaviour was 
observed in two out of four horses administered 0.25 mg/kg. However, a safe and at the same 
time effective dose recommendation of ZUP for horses could not be established in this study.  
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